September 13 at 10:00am CEST, 9:00am BST
*Webinar airing too early or too late for you? This webinar will also be available:
September 13 at 9:30am IST, 12:00pm CST
Liquid biopsy is an emerging area of clinical research, particularly in the context of cancer. As a minimally invasive complementary or alternative approach to tissue biopsies, liquid biopsies are less risky, painful, and costly, and are increasingly being used to analyze biomarkers in liquid samples, such as blood. Recent advances in genomic technologies, such as digital PCR (dPCR)
and next-generation sequencing (NGS), have enabled researchers to more comprehensively detect and study cancer-related mutations, even when they are very rare. With this panel of key opinion leaders in the liquid biopsy space, we dive deeper into the impact of genomics and genomics technologies on the current and future of liquid biopsy clinical research and cancer management. At Thermo Fisher Scientific we are committed to developing robust sample preparation solutions for cell-free nucleic acids and highly sensitive liquid biopsy assays
utilizing both dPCR and targeted NGS to enable cancer driver identification, serial monitoring, and potential recurrence detection.
- Discuss the features of digital PCR and its advantages in liquid biopsy research
- Understand the ways dPCR can be used to support precision medicine research
- Discuss the types of analytes used for dPCR analysis
- Define the current state of dPCR for routine monitoring of cancer patients and future trends
For Research Use Only. Not for use in diagnostic procedures.
Webinars will be available for unlimited on-demand viewing after live event.
Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.